HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohn, D. E. Articles by Fowler, J. M. Search for Related Content PubMed PubMed Citation Articles by Cohn, D. E. Articles by Fowler, J. M. Related Collections Basic Science Genetics and teratology Gynecologic oncology

Improved Survival With an Intact DNA Mismatch Repair System in Endometrial Cancer

From the ¹Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, ²Department of Pathology, ³Department of Medicine, Division of Human Cancer Genetics, and ⁴Center for Biostatistics, the Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio.

OBJECTIVE: To correlate survival and surgical-pathologic factors with DNA mismatch repair status in patients with endometrial cancer.

METHODS: Specimens from 336 patients with endometrial cancer were used to create a tissue microarray. Immunohistochemistry with antibodies against the mismatch repair genes MLH1, MSH2, MSH6, and PMS2 were used to stain the tissue microarray. Clinical, pathologic, and survival data were collected and correlated with the immunohistochemistry results.

RESULTS: Mismatch repair deficiency was seen in 29% (84 of 294) of cases. Correlation was noted between lack of expression of MLH1 and an increased risk for lymphvascular space involvement (32% versus 21%, P=.05) and cervical involvement (26% versus 14%, P=.02). Lack of expression of either MLH1 or MSH2 was associated with thinner patients (85% had a body mass index less than 40 versus 73% of patients with normal expression, P=.02), as well as with the absence of a history of previous primary malignancy (0 verus 13 cases [4%], P=.023). The estimated disease-free survival is 88%; despite a small number of recurrences, there was a nonsignificant improvement in disease-free survival in tumors with an intact mismatch repair system (P=.1). Significantly improved disease-free survival was seen in patients with normal MLH1 and MSH2 expression compared with those with abnormal expression (92% versus 81%, P=.035).

CONCLUSION: Defects in DNA mismatch repair in endometrial cancer is correlated with negative prognostic factors and worse progression-free survival (without a difference in overall survival) compared with tumors with an intact mismatch repair system.

LEVEL OF EVIDENCE: II-3

This article has been cited by other articles:

				B. Y. Karlan, A. Berchuck, and D. Mutch The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice Obstet. Gynecol., July 1, 2007; 110(1): 155 - 167. [Abstract] [Full Text] [PDF]